Uncovering the Clinical Characterization and Mechanisms of Fibrodysplasia Ossificans Progressiva (FOP) By: Sharen Rego

 Introduction

Fibrodysplasia Ossificans Progressiva or FOP is an exceedingly rare, yet severely disabling

genetic disorder, characterized by the abnormal formation of bone tissue outside of the normal human

skeleton (heterotopic ossification). This can occur within soft tissues like the skeletal muscles, tendons,

and ligaments. With an estimated one in two million people affected globally, FOP represents one of the

most complex genetic conditions known to modern medicine. Raising awareness for this disorder is

crucial, as early symptoms are often misdiagnosed as cancer, leading to harmful medical interventions

like biopsies or routine muscle injections which trigger irreversible bone growth.

Main Body

At the cellular level, FOP is caused by a specific mutation in the ACVR1 gene located on chromosome 2.

This gene provides instructions for making a specialized receptor protein that controls when and where

the body builds bone tissue (such as during fetal development or when healing a broken bone). For

individuals with FOP, this mutation damages the receptor, leaving it in an active state. Therefore, the

mutated receptor begins mistakenly reading standard healing signals, which normally promote soft-tissue

repair as a direct command to build solid bone. Consequently, whenever the body experiences

inflammation or minor muscle fatigue, the overactive pathway recruits stem cells to the site and

transforms the surrounding soft tissues into functioning skeletal bone.

In most cases, FOP develops in childhood and presents a distinct physical marker at birth, a

malformation of both big toes at birth. They are shortened and turned inward, but since the condition is so

rare, this indicator is frequently missed, leading to lengthy diagnostic delays. As patients grow, they

experience painful, episodic swellings known as flare-ups. These flare-ups are often triggered by minor

physical trauma, viral illnesses, or muscle strain. Over several weeks, the initial swelling fades, but the

underlying tissue is replaced by permanent, mature bone. This extra bone formation follows a highly

predictable, systematic pattern across the body:

● Front to Back: Moving from the anterior to the posterior parts of the body.

● Top to Bottom: Progressing from the head and neck downward toward the feet.

● Trunk to Limbs: Developing from the spine, shoulders, and hips outward to the arms and legs.

As these bridges of extra bone accumulate, they slowly lock the surrounding joints. When FOP stabilizes

around the spine and rib cage, it severely restricts lung expansion, a condition known as thoracic

insuf iciency syndrome. Additionally, flare-ups in the jaw can permanently lock the joint, presenting

major challenges for eating and dental care.

Why Awareness Matters

Public and medical awareness of FOP is not just helpful, but it is a critical safety requirement for

patient survival. Because FOP affects only one in two million people, the vast majority of primary care

physicians will never encounter a case in their careers. This lack of familiarity leads to a devastating

Rego 2

statistic: nearly 90% of FOP patients are initially misdiagnosed, often with aggressive tissue cancers like

sarcoma.

When a patient is misdiagnosed with cancer, the standard medical response is to perform a tissue

biopsy or surgically remove the mass. For an individual with FOP, these invasive procedures are

catastrophic. The trauma of a biopsy needle or a scalpel slices through muscle tissue, triggering massive,

systemic inflammation. The body's mutated ACVR1 gene reads this inflammation as a command to build

bone, resulting in rapid, permanent joint locking that could have been avoided. Widespread awareness

ensures that doctors recognize the congenital big toe malformation at birth, prompting them to use safe,

non-invasive genetic testing instead of a biopsy.

Beyond medical errors, patients living with FOP face extraordinary daily physical and

psychological challenges. As the secondary skeleton grows, tasks that most people take for granted, like

brushing hair, tying shoes, or reaching for a shelf, become physically impossible. Patients must constantly

navigate a world built for mobile bodies, requiring extensive home modifications, custom wheelchairs,

and dedicated caregiving support.

This is why advocacy, research funding, and community support are so vital. Because the patient

population is so small, global pharmaceutical companies historically had little financial incentive to invest

in finding a cure. Advocacy groups like the International FOP Association (IFOPA) bridge this gap by

raising research funds and connecting families.

These advocacy efforts led directly to recent medical breakthroughs. Doctors can now use

targeted therapies to help manage the disease. For instance, high-dose corticosteroids are used within the

first 24 hours of a flare-up to suppress intense tissue swelling. Even more significantly, regulators

recently approved palovarotene (Sohonos), the first-ever drug designed specifically to target the

bone-growth pathway in FOP. Palovarotene acts as a selective blocker that turns down the overactive

bone-building signals, reducing the total volume of new abnormal bone formation. Continued advocacy

and research are the only pathways toward discovering a treatment that can halt the disease entirely.

Conclusion

Fibrodysplasia Ossificans Progressiva remains one of the most complex biological challenges

in modern medicine. Driven by a single nucleotide mutation in the ACVR1 gene, the condition

fundamentally alters the body's cellular instructions, turning everyday soft tissues into permanent bone.

From the early warning sign of malformed big toes at birth to the predictable, top-to-bottom progression

of joint locking, FOP reshapes a patient's life and challenges their physical independence.

The final takeaway of this research is that while FOP imposes severe physical boundaries, the

medical community is closer than ever to rewriting its future. Increased public awareness protects

vulnerable children from dangerous, unnecessary medical interventions, while global advocacy continues

to fuel the research necessary to develop targeted treatments like palovarotene. By continuing to support

health literacy and rare disease research, the scientific community can move closer to treating the genetic

switch behind FOP and unlocking a better quality of life for patients worldwide.

Rego 3

Works Cited

"Fibrodysplasia Ossificans Progressiva." National Organization for Rare Disorders (NORD),

2023, https://rarediseases.org/rare-diseases/fibrodysplasia-ossificans-progressiva/.

Accessed 26 June 2026.

Kaplan, Frederick S., et al. "The Medical Management of Fibrodysplasia Ossificans Progressiva:

Current Treatment Considerations." International Clinical Council on FOP (ICC) &

IFOPA, 2024, https://www.ifopa.org/care_considerations. Accessed 27 June 2026.

Pignolo, Robert J., et al. "Fibrodysplasia Ossificans Progressiva: Clinical and Genetic Aspects."

Orphanet Journal of Rare Diseases, vol. 6, no. 80, 2011, doi:10.1186/1750-1172-6-80.

National Institutes of Health / PubMed Central.

www.ncbi.nlm.nih.gov/pmc/articles/PMC3253727/. Accessed 27 June 2026.

Qi, Zijuan, et al. "Fibrodysplasia Ossificans Progressiva: Basic Understanding and Experimental

Models." Intractable and Rare Diseases Research, vol. 6, no. 4, 2017, pp. 242–248,

doi:10.5582/irdr.2017.01055. National Institutes of Health / PubMed Central,

www.ncbi.nlm.nih.gov/pmc/articles/PMC5735276/. Accessed 28 June 2026.